ClinicalTrials.gg
RecruitingNCT03231644Updated Aug 12, 2025

Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry

An observational study in Fibrous Dysplasia, McCune Albright Syndrome and Mazabraud Syndrome, sponsored by Tovah Burstein. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-08-12.

Primary conditionFibrous Dysplasia, PolyostoticRegistry: Fibrous Dysplasia of BoneReclassifiedWhy we changed it
Registry
Fibrous Dysplasia of Bone — the first condition term the registry derived for this study.
ClinicalTrials.gg
Fibrous Dysplasia, Polyostotic
Why
  1. The study's listed conditions name Fibrous Dysplasia, Polyostotic, a narrower term within Fibrous Dysplasia of Bone.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Tovah Burstein · Observational

How we know

From the registry’s dates

  • Started Oct 2016; still recruiting 10 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
600
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Fibrous Dysplasia, Polyostotic with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Fibrous Dysplasia, Polyostotic · United States.

Started
2016
the only one that year
Observational
6 of 14
2 open now
Registered
10th of 14
by date
Lead sponsor
1 of 14
Tovah Burstein

Among the 14 studies in Fibrous Dysplasia, Polyostotic with a site in United States, this one is the only one that started in 2016, is one of 6 observational ones, and was the 10th registered.

Fibrous Dysplasia, Polyostotic

23 studies on the registry are indexed under Fibrous Dysplasia, Polyostotic; 5 are open to participants now.

Browse Fibrous Dysplasia, Polyostotic studies →

Open to participants now

2 of the 14 studies in Fibrous Dysplasia, Polyostotic with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Fibrous Dysplasia, Polyostotic studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Fibrous Dysplasia, Polyostotic with a site in United States, or all of them as a file.
02

Study summary

The FD/MAS Patient Registry is an IRB-approved research study that that invites the patients and families to help answer some of the biggest questions about FD/MAS by completing questionnaires about their lives with FD or MAS.

Have you enrolled in the FD/MAS Patient Registry yet? Are you up-to-date on your surveys? Take a trip to www.fdmasregistry.org today to learn more about the project, enroll, complete your surveys, or make sure you aren't due to provide more info!

The FD/MAS Patient Registry: Your story powers research.

Read the detailed description

The FD/MAS Patient Registry is an IRB approved research project that allows patients and families to share their experiences with fibrous dysplasia/McCune-Albright syndrome (FD/MAS) by completing a series of surveys.

The surveys were created in collaboration with patients, parents, clinicians and researchers, so that the data can be used to answer some of the most important questions about FD/MAS, including:

the way the disease develops over time (its "natural history"), the patient experience of the disease, and its impact on quality of life, how and when diagnoses are made, the scope of treatments in use, what surgical techniques work best, and for whom, what other medical interventions work best, and for whom, what social services and therapies are useful, the costs of care to patients and their families, issues that concern patients (such as the impact of pregnancy on FD, or children feeling different and facing stigma), and which research questions and support programs you think are important to fund.

Participation is free and convenient for people with FD/MAS and their legal guardians. You can join today at www.fdmasregistry.org.

03

Conditions studied

  • Fibrous Dysplasia
  • McCune Albright Syndrome
  • Mazabraud Syndrome

Browse trials for

Keywords

  • Fibrous Dysplasia
  • McCune-Albright Syndrome
  • Mazabrauds
  • FD/MAS
04

In context

Fibrous Dysplasia, Polyostotic Reclassified

23 studies on the registry are indexed under Fibrous Dysplasia, Polyostotic; 5 are open to participants now.

Browse Fibrous Dysplasia, Polyostotic studies →

Lead sponsor

This is the only study on the registry with Tovah Burstein as lead sponsor.

Compared within Fibrous Dysplasia, Polyostotic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrous Dysplasia of Bone. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Community sample of all patients in these particular disease communities.

Eligibility criteria

Inclusion Criteria any one or more of the following:

  • clinical diagnosis of fibrous dysplasia
  • clinical diagnosis of McCune-Albright syndrome
  • clinical diagnosis of Mazabraud's syndrome
06

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
600 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • FD/MAS Patients

    Patients with fibrous dysplasia and/or McCune-Albright syndrome and related disorders.

07

What researchers measure

Primary outcomes

  1. Treatment satisfaction

    FACIT-Treatment Satisfaction scale

    Time frame: Through study completion, an average of every 2 years

  2. Perceived symptoms of pain

    Brief Pain Inventory

    Time frame: Through study completion, an average of every 2 years

  3. Depression/anxiety

    Hospital Anxiety Depression Scale

    Time frame: Through study completion, an average of every 2 years

  4. Stigma

    NeuroQol Pediatric and Adult Stigma short forms

    Time frame: Through study completion, an average of every 2 years

  5. Health-related Quality of Life

    SF-36,PedsQL 4.0

    Time frame: Through study completion, an average of every 2 years

  6. Financial health

    FACIT-Cost

    Time frame: Through study completion, an average of every 2 years

08

Study locations

1 of 1 sites recruiting
  • Tovah Burstein
    Bethesda, Maryland 20816-2558, United States
    Recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2016 (actual). Primary completion is estimated for Oct 2028, 144 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2017
First posted
Jul 27, 2017
StartActual
Oct 31, 2016
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03231644
Lead sponsor
Tovah Burstein
Responsible party
Tovah Burstein (Community Engagement Director, Fibrous Dysplasia Foundation) — Sponsor-investigator
First posted
Jul 27, 2017
Start date
Oct 31, 2016
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Aug 12, 2025

Study contacts

Carmel Shemmesh-Rafalowsky
Contact
PI.Registry@fibrousdysplasia.org
Tovah Burstein
Contact
TBurstein@fibrousdysplasia.org
603-325-2489

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion